are members of the German Standing Committee on Vaccination (STIKO).
In consideration of new data and the availability of an additional vaccine for adults, the German Standing Committee on Vaccination (STIKO) has updated its recommendation for the routine vaccination of older adults against pneumococcal diseases.
Updated recommendation
Routine vaccination is recommended for all adults from the age of 60 years. Vaccination shall be given with a vaccine of the greatest possible efficacy against the pneumococcal serotypes currently causing disease in the target group; this is currently the 23-valent polysaccharide vaccine (PPSV23).
In principle, because of the limited duration of protection provided by the vaccine, STIKO considers repeated vaccinations with PPSV23 useful from a medico-epidemiological perspective. The current prescribing information specifies that "healthy adults should not routinely be re-vaccinated", i. e. routine re-vaccination is not covered by the market authorization. However, according to the prescribing information "re-vaccination may be considered for persons at increased risk for severe pneumococcal disease". In this case STIKO recommends a minimum interval of 6 years between vaccine doses.
Seniors who belong to one of the risk groups listed in table 2 of the STIKO recommendations because of a chronic condition (category "I") or because of occupational exposure (category "B") should be vaccinated according to the specific recommendations for these groups.
Seniors who have already been vaccinated with the 13-valent conjugate vaccine (PCV13) should receive a follow-up vaccination with PPSV23 6-12 months after PCV13 to expand serotype coverage.
The objective of the vaccination recommendation is to reduce the number of cases of invasive pneumococcal disease and pneumococcal pneumonia and their consequences, such as hospitalization, disability, and death among older adults in Germany. 
Scientific rationale

Pathogen and clinical presentation
Pneumococci (Streptococcus pneumoniae) are gram-positive encapsulated bacteria. The polysaccharide capsule is a critical virulence factor because it prevents phagocytosis of the pathogen. The antigenic properties of the capsule polysaccharides allow over 90 serotypes to be distinguished, while even more serotypes are still being discovered [1] . Related serotypes are clustered into serogroups. Some serogroups exhibit cross-immunity among the various serotypes belonging to the same serogroup; these include serogroup 6 with the epidemiologically important serotypes 6A and 6B. But there are also serogroups with no cross-immunity of mention between serotypes; e. g. between serotypes 19A and 19F [2, 3] . Pneumococci colonise the human nasopharynx, usually without causing symptoms. However, through local spread they can cause diseases of the upper (sinusitis, middle ear inflammation) and lower (pneumonia) respiratory tract [4] . Invasive pneumococcal diseases (IPDs) are particularly serious. They are defined as the isolation of pneumococci from normally sterile body fluids. The most common forms of IPD are bacteraemia (verified by blood culture) and meningitis (detection in cerebrospinal fluid). Far less often are pneumococci found in pleural, joint, or ascites taps. Different serotypes exhibit different levels of ability to cause invasive diseases [5] .
The most common forms of pneumococcal (Pnc) diseases in adults are community-acquired pneumonia (CAP) and IPD. In adults, IPD manifests mostly as pneumococcal pneumonia with concomitant bacteraemia. A clear delineation between the two manifestation forms is not possible. Presumably, many IPD cases are misssed because often no blood cultures are performed during the diagnostic work-up of a CAP case, or because they show up false negative; e. g. in patients who have already started antibiotic treatment [4] .
Epidemiology
Pneumococci are transmitted by droplet infection from person to person. Small children with asymptomatic nasopharyngeal colonisation are the epidemiologically most important pathogen reservoir. No representative data are available on the prevalence of nasopharyngeal (NP) carriers in Germany. A cross-sectional study conducted in England in 2012-'13, 6 years after universal vaccination of infants with pneumococcal conjugate vaccine (PCV) was introduced, found the prevalence of NP carriers to be 48 % among children aged <5 years, 22 % among ages 5-20 years, and 3 % among ages >20 years. Although the overall prevalence of NP carriers was similar to that in 2001-'02 (before universal vaccination of infants was introduced), the percentage of carriers of the serotypes contained in the currently used PCV13 vaccine dropped from over 75 % to around 5 % in that period [6] .
Incidence of IPD
In Germany there is no nationwide mandatory reporting of pneumococcal diseases. The states of Saxony-Anhalt, Saxony, Mecklenburg-Vorpommern, Brandenburg, and Thuringia each have a statewide reporting obligation for IPD. Higher incidence is reported among children aged <2 years, and older adults (. Fig. 1) . No conclusions on actual IPD incidence can be drawn from these reporting data because the extent of underreporting is unknown. Reasons for underreporting are insufficient diagnostics (blood cultures) and possible noncompliance with reporting obligations.
Since 1997, the Robert Koch Institute (RKI) in Berlin has been conducting voluntary, laboratory-based sentinel surveillance for IPD cases. Until 2006, only IPD cases in children were recorded. In connection with the recommendation for universal vaccination of children, this surveillance was expanded with the online PneumoWeb (www.rki.de/pneumoweb) in 2007 to include people of all ages. The primary aim of PneumoWeb is to monitor the effects of vaccination on serotype distribution in IPD cases in all age groups (see Sect. 4) . In addition to the anticipated reduction in vaccine serotypes, the extent of a potential serotype replacement should also be tracked. Serotype replacement is understood as an increase in serotypes not contained in the vaccine that fill the gap left by the reduction in vaccine serotypes. Consequently, the vaccination's effect on the overall incidence of IPD can be lower than what could be anticipated, based on Tätigkeitsberichte the vaccine's efficacy against the serotypes contained within [7] .
The actual incidence of IPDs cannot be determined from PneumoWeb data because only some of the clinical microbiological laboratories in Germany participate voluntarily in the surveillance. Furthermore, the size of the catchment population of the participating laboratories and the clinics they serve is not known. Assuming that nearly all IPD cases are treated on an inpatient basis, hospital diagnosis statistics offer a better indication of the incidence of IPD cases diagnosed in Germany (see Sect. 6.1, . Table 1 ).
Incidence of pneumococcal pneumonia
Germany has no surveillance system in place that allows estimation of the incidence of pneumococcal pneumonia. We therefore conducted an exploratory literature search of reviews of studies on the incidence of pneumococcal pneumonia in Europe, and linked the findings to data from the German CAPNETZ study [8] and official hospital diagnosis statistics (www.gbe-bund.de) (see Sect. 6.1).
Pneumococcal vaccines
As early as the 1930s, Kaufman proved in a major clinical trial, with around 11,000 participants, that humans can be immunised against a pneumococcal infection through an injection of polysaccharide components of the pneumococcal capsule [9] . Industrially produced vaccines against pneumococci have been available since the 1970s, initially in the form of a 14-valent pure pneumococcal polysaccharide vaccine (PPSV14) with 50 µg of capsule polysaccharide per serotype [2] . This was replaced in 1983 by the 23-valent polysaccharide vaccine (PPSV23), which is still on the market. PPSV23 consists of 25-µg capsule polysaccharides of each of the serotypes that were epidemiologically most important at that time (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), and contains no adjuvant [4] .
Unlike in adults, polysaccharide vaccines exhibit low immunogenicity in children aged <2 years, a group with high incidence of IPD [4] . This led to development of pneumococcal conjugate vaccines (PCVs), in which the polysaccharide antigens are bonded to a carrier protein, resulting in a marked improvement in immunogenicity in infants and young children. But the production process is more complex; therefore, the first licensed conjugate vaccine (PCV7) contained only the antigens of the seven most common serotypes at that time: 4, 6B, 9V, 14, 18C, 19F, and 23F. In February 2001, PCV7 was licensed in the European Union for children aged ≤5 years.
In late 2009, PCV7 was replaced by PCV13, which contains the additional serotypes 1, 3, 5, 6A, 7F, and 19A. In subsequent years, market authorisation was gradually expanded to include older age groups, and in July 2013, PCV13 was authorised for all age groups ≥6 weeks. Since 2009, an additional 10-valent conjugate vaccine (PCV10, Synflorix®) has been available for children aged ≤5 years. It contains serotypes 1, 5, and 7F, in addition to the PCV7 serotypes. The conjugate vaccines contain 1-3 µg (PCV10) or 2.2-4.4 µg (PCV7, PCV13) polysaccharide of each serotype, and aluminium phosphate as an adjuvant.
All serotypes in PCV13 are also present in PPSV23, with the exception of 6A. However, PPSV23 likely provides partial protection against serotype 6A because of cross-immunity with serotype 6B, which the vaccine contains [2, 3, 10] .
Protection from nasopharyngeal colonisation with pneumococci of the serotypes contained in a PCV vaccine has been credibly documented. Therefore, routine PCV vaccination in childhood results in herd protection. Regarding PPSV, however, a review article from 2012 reported that this vaccine led to a reduction in nasopharyngeal colonisation with serotypes contained in the vaccine in only one of four studies cited [10, 11] .
Current STIKO recommendations for pneumococcal vaccination
In 1998, STIKO first recommended pneumococcal vaccination with a polysaccharide vaccine for people aged ≥60 years (called "senior vaccination"), with repeat vaccination after 6 years [12] . In 2009, the recommendation for repeat vaccinations was restricted to certain risk groups; with a one-time vaccination recommended as the standard for older adults. A number of reports of severe local reactions, and contradictory evidence in the medical literature regarding poorer antibody responses after repeat vaccinations, were the reasons for this change [13] . Since then, several further studies have been published, necessitating a reassessment of these issues.
In addition, STIKO recommends pneumococcal vaccination for children, adolescents, and adults at increased risk because of an underlying disease (table 2 in the STIKO recommendations). Since 2006, STIKO has additionally recommended universal vaccination with pneumococcal conjugate vaccine for all infants.
The primary aim of universal vaccination during infancy is reducing the burden of invasive pneumococcal disease including complications, such as hospitalisation, disability, and death, in this age group. Furthermore, a reduction in asymptomatic nasopharyngeal colonisation in vaccinated children, and an associated reduction in the IPD disease burden in (unvaccinated) people in higher age groups through herd protection were also anticipated [14] . STIKO had not defined an explicit objective for the senior vaccination; that is part of this update.
Implementation
The vaccination status of adults was recorded as part of the "Study of the Health of Adults in Germany" (Studie zur Gesundheit Erwachsener in Deutschland, DEGS), conducted by the RKI from 2008 to 2011 [15] . Pneumococcal vaccination uptake among participants aged 65-79 years was 31.4 % (95 % CI, 28.1-34.9 %); slightly higher in women (33.2 %) than in men (29.3 %). Vaccination uptake was significantly higher in the former East Germany, both in women (57.9 %) and men (49.7 %), than in the former West Germany (women, 27.2 %; men, 24.6 %).
Serotype distribution since introduction of universal infant vaccination
PneumoWeb data (. Fig. 2 and 3) show that the percentage of serotypes contained in the conjugate vaccines among all IPD cases has dropped substantially since the recommendation of universal infant vaccination. That drop applies not only to the target age group of young children, but to all age groups; in other words, the anticipated herd protection has occurred. Among ≥60 year olds, the percentage of PCV13 serotypes among IPD cases dropped from about 75 % when universal infant vaccination was introduced in 2007 to 30 % in the 2015-'16 season. To the contrary, the percentage of IPD cases caused by PPSV23 serotypes was about 70 % in 2015-'16. . Fig. 2 shows the relative percentage of the respective vaccine serotypes. . Fig. 3 shows the absolute case numbers for people aged ≥60 years.
Serotype (ST) 3 is a special case; it belongs to the six additional serotypes contained in PCV13 that are not included in PCV7. While the case numbers of the other PCV13 serotypes have steadily decreased since 2007, cases by ST 3 have increased. In the last two seasons, ST 3 was by far the most common serotype, causing almost 20 % of all IPD cases in people aged ≥60 years (. Fig. 3 ). Unlike the other five additional serotypes in PCV13, its percentage among IPD cases in Germany did not drop after the switch from PCV7 to PCV13, in either children or older adults (see . Fig. 4 and [16] ). A similar phenomenon has been observed in other countries [17] [18] [19] .
PCV13 thus appears to provide little or no protection from ST 3 for children, and therefore no, or only limited, herd protection can be expected in other age groups. In an analysis of IPD cases among children in the United Kingdom [20] , the serotype-specific efficacy of PCV13 against ST 3 was by far the lowest; it was the only serotype with a statistically insignificant vaccine efficacy of 26 % (95 % CI, -69 to 68 %). At the same time, the efficacy against the other serotypes in PCV13 (ST 5 was not calculated because of low case numbers) was 82 % (95 % CI, 68-89 %).
It is difficult to assess whether vaccination of adults with PCV13 or PPSV23 can provide protection from illness caused by ST 3 because the number of ST 3 cases is too low in published studies with clinical endpoints or because information on the serotype is missing (see Sect. 6.2). In an evaluation of British IPD surveillance data according to the Broome method, the efficacy of PPSV23 against IPD caused by ST 3 (along with the much rarer ST 1) in older adults was significantly lower than for the other PPSV23 serotypes investigated [21] .
The only randomised controlled trial (RCT) on the efficacy of PCV13 against clinical endpoints in older adults (CAPITA study [22] ) showed statistically non-significant efficacy of 56 % (95 % CI, -6 to 82 %) against PP caused by ST 3 [23] . The efficacy against PP by all 13 vaccine serotypes was 46 % (95 % CI, 23-62 %). These findings align with the assumption that PCV13 has an efficacy against ST 3 comparable with that against the other 12 serotypes, as well as with the assumption that it is significantly less effective against ST 3 -as in children -than against the other serotypes.
A biological explanation could be that the chemical bonding of the capsule polysaccharides in S. pneumoniae serotype 3 (and the epidemiologically insignificant ST 37) to the cell wall is weaker than that of all other serotypes. That trait allows ST 3 to separate its capsule polysaccharides more easily and thus neutralise circulat- Relative distribution of serotypes contained in the different pneumococcal conjugate vaccines of the IPD cases recorded in PneumoWeb, by age group and year of disease PCV7 = serotypes contained in the 7-valent pneumococcal conjugate vaccine, PCV10 = serotypes additionally contained in the 10-valent pneumococcal conjugate vaccine, PCV13 = serotypes additionally contained in the 13-valent pneumococcal conjugate vaccine Since 2012, fewer than 20 isolates have been available for serotyping in the age group 5 -15 years due to very low incidence. Thus the percentages shown for serotype distribution in this age group are subject to a high degree of uncertainty Tätigkeitsberichte ing serum antibodies against ST 3, thereby preventing opsonisation which is necessary for phagocytosis of the encapsulated pneumococci [24] . Immunogenicity studies in adults have also shown significantly weaker immune response to ST 3 than to other serotypes for both PCV13 and PPSV23 [25] [26] [27] [28] . In modelling the epidemiological effects of the vaccination (see Sect. 6.5), the base case rested on the assumption that both PPSV23 and PCV13 are only half as effective against ST 3 as against the other serotypes contained in the respective vaccine. One sensitivity analysis in favour of PCV13 tested the implications of the assumption that PCV13 is as effective against ST 3 as against the vaccine serotypes, yet PPSV23 is only half as effective.
Approach for evaluating the current vaccination recommendation
STIKO took the expansion of the market authorisation of PCV13 to include all age groups, along with finalisation of a major RCT on the efficacy of PCV13 in older adults (CAPITA study, see below), as an occasion to re-examine its current recommendation on the standard vaccination of adults aged ≥60 years ("senior vaccination"). This re-examination focused on: a) Whether older adults should receive one particular vaccine (PPSV23 or PCV13) or both sequentially, in consideration of the changes in serotype distribution since introduction of universal infant vaccination b) At what age the vaccination should be administered c) Whether follow-up vaccinations are beneficial
The aim of the vaccination was defined as a reduction in the number of invasive pneumococcal diseases and pneumococcal pneumonia cases and their consequences, such as hospitalisation, disability, and death, among older adults in Germany.
The following approach was taken to answer the three issues above: The findings of the studies identified for points 2 and 3 were summarised in meta-analyses based on random effects models, using Review Manager 5.2 software [29] . The quality of the evidence was assessed in line with the methods of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group [30] . According to GRADE, evidence quality is a measure of trust in the accuracy of the effect estimate. The quality assessment is judged separately for each investigated endpoint in four levels (high -moderate -lowvery low). Results of RCTs are ranked a priori as "high" quality in GRADE; results of observational studies are ranked as "low" because of the inherently higher risk of bias of this study type. Based on certain criteria defined in the GRADE method, the evidence is examined to determine if it justifies a downgrade or upgrade of the quality level.
Methods and findings regarding the various aspects
Burden of pneumococcal diseases among older adults in Germany
It is difficult to estimate the incidence of pneumococcal pneumonia (PP) because a microbiological diagnosis is confirmed in only a fraction of community-acquired pneumonia (CAP) patients. One reason for this is that in many cases the patient receives a calculated antibiotic therapy without any effort to establish the pathogen; that is the rule in CAP cases treated on an outpatient basis. Another reason is that the viability of pneumococci outside the human body is limited. This reduces the sensitivity of microbiological cultures from blood or sputum samples under routine conditions, often with long transport times to the laboratory. Microbiological cultures are also usually negative in patients who have begun antibiotic treatment. The widespread urine antigen test BinaxNOW® S. pneumoniae (Alere GmbH, Cologne, Germany) has a sensitivity of only 63-82 %, with a specificity of 78-100 % [31] , depending on the study.
An exploratory literature search in MEDLINE, and a survey of experts in the STIKO pneumococci workgroup, failed to produce any studies that provided a direct estimate of the incidence of PP in Germany. It can be assumed that the vast majority of PP cases are community-acquired [4] . For that reason, we estimated the incidence of PP by multiplying the incidence of all CAP by the percentage of CAP cases caused by pneumococci as determined in other studies.
The CAPNETZ study [8, 32] is the largest prospective study on the microbiologi- [33, 34] . The percentage of PP among all CAP cases in the included studies ranged from 0-67 % [33] and 12-85 % [34] . The causes of this gaping difference are more likely differences in the diagnostic tests conducted, case definitions, and patient collectives, rather than real differences between countries or studies [33] . Based on a meta-analysis (random effects model) of 77 individual studies, with a total of 24,410 CAP patients, Rozenbaum et al. [33] estimate the percentage of PP as 19.3 % (no CI is given) of all CAP cases in which a pathogen was detected.
A study of adults in Finland aged ≥65 years [35] , which was published after the review by Rozenbaum et al., found a higher percentage of PP (30 %; 56 of 187 CAP cases with pathogen detection), but the PP diagnosis was sometimes confirmed serologically (antibodies against pneumococcal surface adhesin A or choline-binding protein A). The percentage of PP among all CAP cases in the placebo arm of the CAPITA trial was only 22 % (174 of 787 CAP cases), although a specially developed, highly sensitive urine antigen test was used to detect PCV13 serotypes. There is no information in the publication [22] on the number of CAP cases with detection of any pathogen.
. Table 1 shows case numbers from the hospital diagnosis statistics for Germany (www.gbe-bund.de). Less than 1 % of all pneumonia cases were coded as PP (ICD10 code J13); most certainly a significant underestimation of the actual percentage. Based on the data reported by Rozenbaum et al. [33] and from the CAPITA study, we estimate that pneumococci caused roughly 20 % of all cases coded with any ICD10 code for pneumonia (J12-J18 This statistic includes only those deaths that occurred during hospitalisation; the actual mortality is likely higher. In the CAPNETZ study, the 30-day case fatality of PP cases in people aged ≥60 years was somewhat lower, at 7.7 % (32 of 418 cases). Notably, this number includes outpatient PP cases, which are probably less lethal than inpatient cases. There is also a selection bias in CAPNETZ in favour of those less severely ill, because only patients capable of giving consent were included in the study (Mathias Pletz, personal message, 12. 2. 2015).
Efficacy of one-time vaccination with PPSV23 or PCV13 against clinical endpoints in older people
Authors GF and CR conducted a systematic literature search for studies on the efficacy of pneumococcal vaccines against clinical endpoints. A two-stage strategy was used to identify relevant studies. First, original works published in or before 2011 were identified using the broad-based Cochrane review "Vaccines for Preventing Pneumococcal Infection in Adults, " from 2013 [36] , scrutinising the lists of both included and excluded studies. Studies published after 2011 were then identified using a search strategy adapted to the Cochrane review in the databases MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, on 3 July 2015 (Flowchart see . Fig. A1 in the Appendix). An updated search on 15 July 2016 yielded no additional hits. The systematic literature review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement [37] .
Study selection was based on PICO questions defined by STIKO (. Table 2 ). In addition to RCTs, observational studies (cohort and case-control studies, including case-case studies using the Broome method [56] ) were included as long as results were adjusted for relevant confounders (e. g. age, comorbidities). Risk of bias of included studies was assessed using the Cochrane Risk of Bias Tool [57] for RCTs and the Newcastle-Ottawa Scale [58] for observational studies.
No evaluation was conducted on the endpoints "all-cause CAP" and "all-cause mortality" because the sizes of the individual studies were insufficient to determine or rule out an effect on these endpoints with adequate statistical power. See also the discussion in [43] and the calculations in [59] .
Direct comparison PPSV23 vs. PCV13
Only one study with a direct comparison of the efficacy of PPSV23 and PCV7 against clinical endpoints in older adults was found [60] . In this randomised, non-blinded study, chronic obstructive pulmonary disease (COPD) patients aged ≥40 years (mean, 63.5 years) were vaccinated with PPSV23 or PCV7. The primary endpoint of the study was immunogenicity data. Of the endpoints defined in our PICO questions, only overall mortality was reported. Among 80 participants in each of the two groups monitored over 2 years, 4 participants in the PCV7 group and 7 in the PPSV23 group died (odds ratio [OR] = 0.55; 95 % CI, 0.15-1.95). The extremely wide CI, which also includes the value 1, does not permit a comparative assessment of the two vaccines.
PPSV23
The efficacy of polysaccharide vaccines was investigated in numerous RCTs already summarised in several meta-analyses. At the time of our own literature searches, the Cochrane review by Moberley et al. [36] and a review by Huss et al. [61] were the most recent ones. Because different studies were included or excluded, the findings of those two reviews are contradictory in some points; see also the correspondence between the authors [62, 63] . Problematic about the two reviews (and other older reviews) is that they pool data from RCTs of adults of various age groups, with various polysaccharide vaccines (different valencies, different quantities of antigen), inconsistent case definitions, and of populations with highly varying base risk of pneumococcal diseases [59] .
For that reason, we conducted our own meta-analysis, including only those RCTs that meet the criteria set forth in the PICO questions (. Table 2 )-a total of 4 RCTs. In light of the low case numbers in these RCTs and the resulting broad CIs of the pooled estimates, we also analysed observational studies (. Table 3 ).
Evidence from RCTs. . After exclusion of two trials with a high risk of bias, the pooled vaccine efficacy of PPSV23 against pneumococcal pneumonia is 64 %, with a moderately wide CI (95 % CI, 35-80 %). Because many cases were diagnosed using a urine antigen test, there are no data on VE against PP caused by vaccine serotypes.
In modelling the various vaccination strategies, the VE estimates were interpreted as efficacy against IPD or PP caused by vaccine serotypes, thus providing a conservative assessment of PPSV23.
The meta-analysis for the endpoint IPD showed no heterogeneity. Regarding PP, the meta-analysis of all 4 RCTs showed considerable heterogeneity (I 2 = 78 %), which disappeared after exclusion of the 2 RCTs with a high risk of bias (I 2 = 0 %).
Considerations for inclusion and exclusion of individual RCTs. 1. The results of the previously published meta-analyses by Moberley et al. [36] and Huss et al. [61] were greatly influenced by the trials by Honkanen et al. [41] and Örtqvist et al. [40] . We included these two trials for the endpoint IPD, but not for the endpoint PP because in a large number of cases in both studies, the PP diagnosis was based on detection of pneumolysin IgG in serum [54] or in circulating immune complexes in serum [55] , using poorly validated inhouse ELISAs. Serum samples from both studies were tested at the same laboratory in Finland where the in-house ELISAs had also been developed. It later became evident that their specificity was insufficient for vaccination efficacy studies.
(a) In the original publication by Jalonen et al. [54] , pneumolysin IgG was measured in paired serum samples of 159 patients (range, 16-95 years old; mean, 63 years) with radiologically confirmed pneumonia. Paired serum samples of 27 patients with bacteraemia caused by other pathogens, and one-time serum samples from 29 healthy blood donors (mean age, 50 years) served as controls. A "positive" result was defined as an antibody concentration exceeding the 99th percentile of healthy controls in at least one of the paired serum samples, or a ≥ 2-fold titre increase. For an ELISA, this cut-off is unusually low (a 4-fold or greater increase is common) because a 2-fold increase can often be observed even in repeated measurements of the same serum sample, as a result of measurement inaccuracies.
The sensitivity of the test is reported [55], using pneumolysin from E. coli as the antigen. They found pneumolysin antibodies in circulating immune complexes in 60 % of the patients with non-bacteraemic PP, 63 % of the healthy patients with pneumococcal colonisation, 44 % of the stable COPD patients, and 23 % of the healthy controls (aged 50-64 years). In bacteraemic patients antibody concentrations in the acute phase were lower than, and the reconvalescence phase similar to those in non-bacteraemic pneumococcal pneumonia patients and subjects with pneumococcal colonisation. The authors conclude that the ply-IC test does not allow a distinction between pneumococcal disease and colonisation, and is therefore unsuitable as a method for estimating disease burden caused by pneumococci or diagnosing pneumococcal pneumonia in vaccine efficacy studies [66] . 2. After completion of our meta-analysis, two further meta-analyses of the efficacy of PPSV23 in older adults were published in 2016 [67, 68] . (a) The meta-analysis by Schiffner-Rohe [67] was commissioned by Pfizer and all authors were employees of the company or a consulting firm working for it. Because Pfizer is the manufacturer of the competing product PCV13, the authors have a strong conflict of interest. The authors only considered RCTs. They argue that the RCT by Maruyama et al. [39] should not be considered. They state that the study population was not representative of the STIKO recommendation's target group because it consisted of retirement home residents, and because the study was conducted in Japan, not Europe. However, following this argument, the RCT by Örtqvist et al. [40] , which Schiffner-Rohe included, should also have been excluded because all study participants had been treated for pneumonia as inpatients and were later vaccinated with PPSV23 or placebo. This population is also not representative of the target group of the STIKO recommendation. (b) Kraicer-Melamed et al. [68] meta-analysed the efficacy of PPSV23 against IPD, all-cause CAP, and PP in RCTs and observational studies. They used "living in retirement homes" as an exclusion criterion for the literature search, without further justification. Thereby they excluded the Maruyama et al. RCT but included the RCTs by Örtqvist et al. and Honkanen et al. [41] . Nevertheless, the authors concluded that the available data indicated efficacy of PPSV23 against IPD and did not exclude efficacy of PPSV23 against all-cause CAP.
The participants in the RCT by Maruyama et al. were in fact older, and probably had more comorbidities than the av-erage person aged ≥60 years in Germany. It is not clear whether that had any impact on the observed vaccine efficacy. In STIKO's opinion there is no plausible biological reason why PPSV23 should be more effective in this study population than in healthier people or the younger of older adults. Thus, the efficacy achievable with PPSV23 in the target group of the STIKO recommendation is more likely to be underestimated than overestimated through inclusion of the Maruyama study. The same applies to the RCT by Örtqvist et al., which we included in our meta-analysis for the endpoint IPD. Its exclusion for the endpoint PP was not due to any questionable representativeness of the study population, but rather, as explained above, because of its use of the pneumolysin antibody test with doubtful specificity for the diagnosis of PP. For the same reason, we did not consider the Honkanen et al. study [41] for the endpoint PP in our meta-analysis.
Evidence from observational studies.
One essential problem of observational studies is that the respective groups of vaccinated and unvaccinated people frequently differ with regard to underlying diseases and other health-related factors (e. g. lifestyle). Correspondingly, the basic risk of pneumococcal disease can be different in the two groups, even without vaccination. That can lead to a distortion of the observed relative risks (i. e. confounding). For that reason, we included only studies in which important confounders (at least age and comorbidities) were recorded and taken into account in an adjusted statistical analysis. Three registry-based cohort studies [43, 44, 46] , 3 matched case-control studies [47] [48] [49] , and 4 "case-case studies" using the Broome method [21, [50] [51] [52] fulfilled this condition. Efficacy against PP was also investigated in a study with a similar case-case design, in which pneumonia cases caused by other pathogens or with no identified pathogen were used as the control group [53] . A large registry-based cohort study from Sweden [69] was excluded because it did not take confounders into account. Not all publications reported findings on all endpoints of interest to us.
We used the adjusted odds ratios (OR) for the meta-analyses (. Fig. 6 ). In the cohort studies (. Fig. 6a) , the pooled point estimates of the vaccine effectiveness against IPD by any serotype was 45 %, and 48 % against PP. This is lower than the corresponding figures in the RCTs, though the CIs overlap widely. The pooled vaccine effectiveness against IPD (by any serotype) in the case-control studies (. Fig. 6b ) was 59 %; this figure falls between the results of the RCTs and the cohort studies. Effectiveness was lower in the most recent study, conducted by Leventer-Roberts et al. [48] . That may be because the percentage of IPD cases caused by serotypes contained in PPSV23 had al- Table 3 of the publication for the combined group of ≥65-year-olds vaccinated in the past 0-<2 or 2-<5 years, excluding the immunocompromised group Tätigkeitsberichte ready dropped because of infant vaccination with PCV7 when the study was conducted in 2008-2010. Correspondingly, the effectiveness against IPD caused by vaccine serotypes (VT-IPD) in the older case-control studies was only slightly higher than that against IPD caused by any serotype, because the percentage of non-PPSV23 serotypes was low at the time these studies were conducted. The pooled effectiveness against VT-IPD in the case-case studies using the Broome method (. Fig. 6c) was lower, at 39 %. The reason for this is not apparent.
The pooled vaccine effectiveness against pneumococcal pneumonia caused by any serotype was similar across all study types: 48 % in cohort studies, 48 % in one case-control study, and 37 % in one casecase study, with broadly overlapping CIs. Because many of the cases were diagnosed using urine antigen test, there is no separate information on the efficacy against PP caused by vaccine serotypes.
PCV13
The efficacy of PCV13 against clinical endpoints in people aged ≥65 years was investigated in a large placebo-controlled RCT (CAPITA trial) in the Netherlands, where there is, to date, no general recommendation of pneumococcal vaccination for older adults. The results were reported in March 2015 in a peer-reviewed publication [22] . Additional information on the study design can be found in [70] .
The study participants were recruited between September 2008 and January 2010 among residents of the Netherlands aged ≥65 years (mean, 72.8 years). Exclusion criteria included immunodeficiency, immunosuppression, earlier vaccination against pneumococci, or residence in a retirement home [70] . Approximately 42,000 participants were vaccinated with PCV13 and around 42,000 with placebo, and followed-up for a mean of 4 years. In addition to the usual methods for diagnosing PP, a specially developed urine antigen test was used. This assay selectively detects antigens of the pneumococcal serotypes contained in PCV13 [71] . That allowed cases caused by vaccine serotypes (VT-PP) to be distinguished from those caused by non-vaccine serotypes, even in non-invasive pneumococcal pneumonia.
In the per-protocol study population, 7 cases of VT-IPD occurred in the vaccinated group and 28 in the placebo group, equalling a vaccine efficacy of 75 % (95 % CI, 41-91 %) against VT-IPD. Thirty-three cases of non-invasive VT-PP occurred in the vaccinated group and 60 in the placebo group, equalling a vaccine efficacy of 45 % (95.2 % CI, 14-65 %) against non-invasive VT-PP. The efficacy of PCV13 against IPD caused by any serotype was 52 % (95 % CI, 22-71 %); against non-invasive PP by any serotype it was 24 % (95 % CI, -6 to 46 %).
Case patients who were immunocompetent at the time of vaccination, but who later developed immunodeficiency, were excluded from the per-protocol population. These individuals were included in the "modified intention-to-treat analysis". This analysis, which reflects the real life situation better than the per-protocol analysis, showed a vaccine efficacy of 76 % (95 % CI, 47-90 %) against VT-IPD and 41 % (95.2 % CI, 13-61 %) against non-invasive VT-PP. The vaccine efficacy against IPD caused by any serotype was 49 % (95 % CI, 21-67 %); against non-invasive PP caused by any serotype it was 17 % (95.2 % CI, -10 to 38 %) see . Fig. 7 .
The group of excluded participants, i. e. those who developed immunodeficiency in the period between vaccination and disease, exhibited no statistically significant vaccine efficacy of PCV13. This may have been due to the small number of cases (4 cases of VT-IPD, 17 cases of non-invasive VT-PP). Arithmetically vaccine efficacy against non-invasive VT-PP in this group was 30 % (95 % CI, -105 to 78 %) [23] .
The CAPITA trial demonstrated a statistically significant vaccine efficacy of PCV13 against IPD (VT and any serotype) and against non-invasive PP by vaccine serotypes. However, no significant efficacy was observed against non-invasive PP by any serotype. This holds true for both the per-protocol and the modified-intention-to-treat analysis.
Quality of evidence based on GRADE criteria
Regarding PPSV23, we ranked the quality of the evidence for both endpoints (IPD, PP) at the second-highest level, "moderate". RCTs are primarily classified as high-quality evidence in GRADE. The downgrade owed to the wide CIs of the efficacy against IPD and a study population that deviates from the PICO question (indirectness) for the endpoint PP (see GRADE profile . Table A1 in the Appendix). That results in a degree of uncertainty regarding the actual level of the efficacy of PPSV23.
Regarding PCV13, we ranked the quality of evidence as "high" for the endpoint VT-IPD, and as "moderate" for the endpoint VT-PP, because of the wide CI (see GRADE profile . Table A2 in the Appendix). We did not assess the quality of evidence for the endpoints IPD and PP caused by any serotype because the observed efficacies were largely determined by the local serotype mix at the time of the study. Because infants in the Netherlands were vaccinated with PCV7 or PCV10 at the time of the CAPITA study, the serotype mix is not comparable to the current situation in Germany, where herd protection by universal infant vaccination with PCV13 since 2010 has led to a significant drop in PCV13 serotypes (except ST 3) in all age groups.
Comparative assessment of efficacy data for PPSV23 and PCV13
The point estimates from RCTs for efficacy against IPD caused by serotypes contained in the respective vaccine are nearly identical: 73 % for PPSV23 and 76 % for PCV13 (modified intention-to-treat analysis). The efficacy of PPSV23 against PP caused by any serotype was significantly higher (64 % in RCTs and 48 % in cohort studies) than that of PCV13 (17 %), and similar to the efficacy of PCV13 against vaccine-type PP (41 %). However, the CIs are so wide that a comparative assessment of the two vaccines is scarcely possible. Thus, it cannot be ruled out with certainty that one of the two vaccines may have a greater or lower efficacy to a relevant degree.
With regard to the endpoint PP, the data on vaccine efficacy from RCTs are based on only one RCT with PCV13 (CAPITA study) and only 2 RCTs with PPSV23. Furthermore, the pooled vaccine efficacy of PPSV23 is largely determined by the Maruyama et al. RCT. None of the 3 RCTs investigated a study population completely representative of the STIKO recommendation target group. On average, the participants in the trials by Maruyama et al. and Alfageme et al. were older and/or (probably) had more comorbidities, which may lead to underestimation of the vaccine efficacy achievable by PPSV23 among older adults in Germany. Conversely, the efficacy of PCV13 among older adults in Germany is probably lower than that recorded in the CAPITA trial because CAPITA only included people without immunodeficiency or immunosuppression.
It is often claimed that the protection offered by the pure (non-conjugate) polysaccharide vaccine against PP has not been proved (e. g. [22, 61] ). However, the current Cochrane review from 2013 [36] shows a pooled efficacy of 28 % (95 % CI, 7-44 %) against all-cause pneumonia. This means that efficacy against PP must be higher, because only a fraction of all CAP cases is caused by pneumococci. Studies of very different populations (i. e. young and old, developed and developing countries) were included in that meta-analysis, leading to a large heterogeneity of the results. Polysaccharide vaccines demonstrated high efficacy against PP in several classic RCTs conducted in the 1970s among young South African goldminers, who had a very high risk of pneumococcal pneumonia. In this population, highly significant vaccine efficacies of 76-92 % against VT-PP have been observed for various experimental 6-, 12-, and 13-valent PPSVs [72, 73] . Even though these findings cannot be applied quantitatively to people aged ≥60 years, or to the current PPSV23 vaccine, they do impressively demonstrate the proof of principle that pure polysaccharide vaccines can provide protection from PP.
From a pathophysiological perspective, it appears implausible that protection from non-bacteraemic pneumonia should solely depend on prevention of pneumococcal colonisation of the upper respiratory tract through mucosal antibodies. When a colonised person aspirates pneumococci it leads to a local inflammatory reaction with the exudation of plasma (oedema fluid) into the alveoli. The emergent plasma antibodies and complement components cause opsonisation of the pneumococci in the alveoli and, thus, induce their phagocytosis and killing [74] . Thereby, plasma antibodies also contribute to preventing clinical manifestation of pneumonia. The result of the Maruyama et al. [39] RCT, in which an efficacy of 62 % (95 % CI, 30-79 %) of PPSV23 against PP by any serotype was observed in retirement home residents, underscores this view.
With regard to the population-based impact achievable by the two vaccines, it must be noted that the serotypes contained in PCV13 have regressed considerably since the use of PCV7 and PCV13 for infant vaccination. In the 2015-'16 season they caused only 30 % of the IPD cases in people aged ≥60 years in Germany. In contrast, serotypes contained in PPSV23 caused 70 % of the IPD cases in this age group (. Fig. 3) . The consequence is that vaccination with PPSV23 can prevent more IPD cases at the population level than PCV13, even if the efficacy of PPSV23 were only half that of PCV13.
No recent data are available on serotype distribution in non-invasive PP cases in Germany because, in these cases, often no pathogens are cultivated (e. g. from sputum) and the diagnosis is based on a positive BinaxNOW® urine antigen test, which does not allow for serotype differentiation. Presumably serotype distribution is influenced by herd protection through infant vaccination in a similar manner as in IPD cases. In Denmark, serotype distribution in PP cases in adults was investigated in 2011, 1 year after the switch from PCV7 to PCV13 in the infant vaccination programme [75] . In PP cases with bacteraemia (i. e. IPD cases), the proportion of PCV13 serotypes was 59 % (95 % CI, 48-70 %), and that of PPSV23 serotypes was 87 % (95 % CI, 74-100 %). A similar relative distribution, though at a lower level, was found among non-bacteraemic PP cases (pathogen cultivation from sputum, pleural punctate, or bron- Rodrigo et al. [76] studied the serotype distribution among mostly non-bacteraemic PP cases in adults (median age, 71 years) in England. Over 5 years (September 2008 to August 2013) 2,229 in-patients with CAP at two major hospitals in Nottingham were included. In 653 (29 %) of these patients, PP was diagnosed, thereof 87 (13 %) with bacteraemia. In April 2010, approximately half way through the study, the infant vaccination programme in England switched from PCV7 to PCV13. Compared with the study period before the switch to PCV13, a reduction in PP cases caused by PCV13 of approximately 40 % occurred thereafter. The greatest reduction was in serotypes also contained in PCV7 (-88 %); while the six extra serotypes contained in PCV13 dropped by 30 %. It is not surprising that the six extra serotypes dropped less, because only the first 3 years after the switch to PCV13 in the infant vaccination programme were investigated, and it can take several years for herd protection effects to accumulate [77] .
Duration of vaccine protection
The duration of protection provided by PPSV23 can be roughly estimated through an overall assessment of the findings of our meta-analyses. The vaccine efficacy of PPSV23 observed in the RCTs applies to a follow-up period of 2-3 years after vaccination. In contrast, a variable -on average longer -period following vaccination was investigated in the cohort studies because many of the participants had already been vaccinated several years before recruitment. This probably explains why the observed vaccine effectiveness in the cohort studies was lower.
The effectiveness for PPSV23 of 48 % against PP and 62 % against IPD cited for the cohort studies by Ochoa-Gondar et al. [44] in this report apply to people who had been vaccinated in the previous 5 years, compared with people never vaccinated against pneumococci. People who had "ever [been] vaccinated" (i. e. including vaccinations >5 years ago) did not have a significantly lower illness rate than those never vaccinated. That means that no significant protection was detectable for the period exceeding 5 years after vaccination.
Andrews et al. [21] arrived at similar results in their calculation of PPSV23 effectiveness using the Broome method. For people aged 65-74 years, effectiveness against VT-IPD was 65 % (95 % CI, 23-84 %) within <2 years after vaccination and 62 % (95 % CI, 21-82 %) in the period 2-5 years after vaccination. More than 5 years after vaccination, a significantly lower, and statistically no longer significant, effectiveness of 28 % (95 % CI, -72 to 70 %) was found (Table 4 in [21] ).
These data suggest that vaccine efficacy after a one-time vaccination with PPSV23 declines continuously from a relatively high level shortly after vaccination. As soon as 5 years after vaccination a large portion of those vaccinated may no longer be protected.
Regarding duration of protection after vaccination with PCV13 of older adults, the CAPITA study [22] provides the only available data. No significant reduction in vaccine efficacy was detected during the 4-year follow-up period in this RCT. However, the case number in the fourth year was so low that an onset of reduction cannot be ruled out. Data from children's vaccination suggest that the duration of protection provided by a one-time vaccination with PCV13 is limited [78] .
Reactogenicity and safety of a one-time vaccination with PPSV23 or PCV13
Authors SG and TH identified studies on the reactogenicity and safety ("safety aspects") of PPSV23 and PCV13 in older adults by using a systematic literature search based on the PICO questions in . Table 4 . See . Fig. A2 in the Appendix for the search strategy and flow chart.
Three studies (two RCTs and one cohort study) on safety aspects were found for PPSV23, and two RCTs for PCV13. Inactivated influenza vaccine (IIV) was administered at the same time to both the intervention and control groups. Data on safety aspects from the CAPITA study (RCT PCV13 vs. placebo) available in the form of a supplementary appendix [23] since March 2015 were taken into account retroactively. Safety aspects in a direct comparison between PPSV23 and PCV13 were investigated in three RCTs (. Table 5 ).
. Table 6 lists the results of the studies on PPSV23 or PCV13. The publication by Grilli et al. [79] contained no evaluable data. Information on the endpoint "unplanned medical visits" was found only in D' Alessandro et al. [81] . A total of 305 people (1 % of the study population) had an unplanned medical examination, 1.3 % in the intervention group and 0.9 % in the control group. Four people -all vaccinated with PPSV23 and IIV -were hospitalised because of dyspnoea with malaise, long-lasting fever, bronchopneumonia, or circulatory collapse, though it is unclear whether there was a causal relationship with the vaccination.
PPSV23 + inactivated influenza vaccine (IIV) vs. IIV alone
The assessment was based on the studies by Honkanen et al. [80] and D' Alessandro et al. [81] Unplanned medical visits, muscle pain, joint pain, local reactions, and/or malaise/fatigue occurred significantly more frequently among those vaccinated with PPSV23 than in the control group. There was no significant difference in frequency of fever and headache. The GRADE-ing of the best available evidence resulted in "very low" to "low" quality of the evidence for the investigated endpoints (see GRADE profile . Table A3 in the Appendix).
PCV13 (+IIV) vs. placebo (+IIV)
In the three evaluated RCTs [23, 82, 83] , those vaccinated with PCV13 reported muscle pain and local pain significantly more often (GRADE: "moderate" quality of evidence). Fever, malaise, headache, muscle and joint pain occurred more frequently among those vaccinated with PCV13, but the differences were not (or not in all three studies) significant (GRADE: "low" and "moderate" quality of evidence, respectively. See GRADE profile . Table A4 in the Appendix)
PPSV23 vs. PCV13
In the direct comparison of the two vaccines (. Table 7 ) there was a consistently higher percentage of muscle pain among PPSV23 recipients across all evaluated studies. Only slight differences were detected for the other investigated safety endpoints, without a clear trend in favour of either vaccine. Only percentages were reported in the three RCTs. It is not possible to translate these back into absolute numbers. For that reason, an assessment based on GRADE could not be conducted.
Summary and assessment of the safety aspects
For the most part, more adverse events occurred in the intervention groups than in the control groups, regardless of the vaccine being PPSV23 or PCV13. The quality of evidence is in the area of "very low" to "moderate". Frequency of side effects must not be compared across studies with PPSV23 + IIV and PCV13 + IIV because of the different follow-up periods and recording methods.
In the direct comparison of PPSV23 and PCV13, muscle pain was observed more frequently after PPSV23, but the difference was significant in only one of the three studies. The other investigated endpoints appear to occur with similar frequency after both vaccines, but there are some major differences in the reported frequency of individual endpoints (e. g. fever) between studies. The presentation of the data in the publications does not allow meta-analysis.
Based on the limited data available, no important differences in reactogenicity between PPSV23 and PCV13 could be detected. However, there are no studies on possible side effects that occur >14 days after vaccination, and the sizes of the identified studies are insufficient to detect rare potentially serious side effects.
Efficacy and reactogenicity of repeated vaccination with PPSV23
Approach
To assess this question, authors CR, TH, and GF on 26 June 2015 conducted a systematic literature research based on the PICO questions in . We followed the PRISMA directives [37] in conducting the systematic literature review. A detailed report of our review has been accepted for publication in BMC Infectious Diseases (Remschmidt et al.) .
The literature search resulted in 1,162 returns, of which only 14 studies [26, 27, 60, [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] met the inclusion criteria (see . Table 9 ). We excluded studies that examined only immunosuppressed patients (e. g. HIV-positive patients or kidney transplant patients), in which a different vaccine formulation (e. g. PPSV14) was used, or in which the repeat vaccination was administered within 1 year of the initial vaccination. Data on clinical endpoints were not reported in any of the included studies. Nine studies reported immunogenicity data, and 10 reported data on safety and reactogenicity.
Immunogenicity
Immunogenicity data were reported in 9 studies [ Significantly different values in bold.
The majority of subjects in both study arms were also vaccinated against influenza. In the safety population the influenza vaccination was administered at least 7 days before or after the PCV13 or placebo vaccination, Local reactions of all types (pain, swelling, redness); pain not reported separately levels were measured in 8 studies with different ELISA assays; the consensus ELISA recommended by WHO was used in only 2 studies. Five studies used an opsonophagocytic activity (OPA) assay.
We did not pool the data because the antibody (AB) levels are not comparable across studies (different laboratory assays, AB against different serotypes measured, different populations, different time intervals between vaccination and blood sampling). To compare the results of AB levels across studies, we calculated within each individual study the ratio of the AB level at identical time points after (or before) the second and first dose of PPSV23. This dimensionless ratio allows comparison of the results of the various studies. A ratio of >1 means that the AB level was higher at the same point in time after the second dose than after the first.
In general, the AB levels before the second dose (3-10 years after the first dose) were higher than in PPSV23-naive individuals before the first dose. At 1 and 2 months after vaccination, the ratio was mostly between 0.7 and 1; i. e. shortly after the second dose the rise in AB levels was less marked than after the first dose (. Fig. 8 ). Only two studies measured AB levels 1 or 2 years after vaccination. The ratio for most serotypes was close to 1 in Dransfield et al. [60] . In Musher et al. [27] the ratio was >1 after 2 years; i. e. AB levels were higher on average after the second PPSV23 dose. In all four studies in which the AB levels were measured 5-10 years after the second dose, they were consistently higher than, or at least as high as, 5-10 years after the first dose (ratio ≥1).
Musher et al. [27] also examined AB levels after a third dose administered 10 years after the second. One month after the third dose, the AB levels were somewhat lower than 1 month after the second dose, but it must be taken into account that the study participants were 10 years older at the time of the third vaccination.
These results refute a sustained hyporesponsiveness after follow-up PPSV23 vaccinations in adults. They concur with comparative analyses in older adults (aged 50-80 years), who exhibited similar quantities of anti-PPS antibody producing plasma cells and memory B cells in peripheral blood (measured by ELISPOT without or with restimulation) 1 week or 2 years after vaccination with PPSV23 or PCV7 [98, 99] . The reduced frequency of memory B cells in peripheral blood through PPSV23, described but mechanistically not yet defined by a different workgroup, was mostly limited to a period of 4 weeks after vaccination. After 6 months, the number of peripheral memory B cells in the PCV7 and PPSV23 groups had fallen to a similar level [100] .
As T-cell-independent antigens, pneumococcal polysaccharides (PPS) do not trigger a stronger immune response after repeated immunisation. However, various studies have shown that PPS induce efficient activation of IgM 
CD27
+ switched memory B cells. This causes a lower anti-PPS IgM response after PPSV23 vaccination, while the anti-PPS IgG response (as is the opsonisation activity of the serum) is preserved by stimulation of switched memory B cells [109] [110] [111] [112] . Although the lower IgM response may negatively influence vaccine efficacy, these findings, on the whole, indicate that PPSV23 is immunogenic also in older adults.
Reactogenicity and safety of re-vaccinations
We identified 10 studies that compared the frequency of adverse drug reactions (ADRs) after a first and second vaccination with PPSV23. Five [27, [88] [89] [90] 93] were prospective studies in which the participants recorded ADRs in a diary for 14 days after vaccination. Four studies [91, 94, 95, 97] used large databases to identify unplanned medical visits (i. e. emergency room, hospitalisation) 1-30 days after the respective vaccination. In one study [87] vaccinated people were asked retrospectively by telephone about ADRs. As these interviews did not take place until 8 months after the vaccination, there are considerable doubts about the accuracy of the answers. For that reason, we have excluded this study from further analyses.
Results
Across studies, fever (0-9 % after first dose, 0-10 % after second dose) and unplanned medical visits (0.3-2.2 % in total) were reported with similar frequency. For other ADRs there were marked differences across studies; for example, headache was reported by 2-61 % of the vaccinees after the first dose, and in 13-57 % after the second dose.
Depending on the endpoint, 1-3 studies reported significantly more unplanned medical visits, headache, general malaise, muscle pain, joint pain, severe local pain, and/or limitations in arm movement after the re-vaccination than after the initial vaccination. No significant differences were found with regard to fever or severe ADRs.
In a stratified analysis, two studies [27, 94] found significant differences in the rate of ADRs only if the interval between the first and second dose was <5 years. If the interval was >5 years [94] or 10 years [27] , the difference was described as no longer statistically significant. In participants who received a second dose of PPSV23 5-13 years after the initial vaccination, Jackson et al. [89] found no statistically significant dependence of the ADR frequency on the interval between the vaccinations. However, there was a significant correlation of ADR frequency to AB levels shortly before the second dose.
Some studies also reported ADRs after further (third and fourth) PPSV23 vaccinations. No additional increase of ADRs could be clearly observed.
In summary, the rate of non-severe ADRs was higher after re-vaccination than after the initial vaccination. Data indicate that an interval of <5 years between the first and second vaccine dose is associated with higher ADR frequency. Additional vaccinations (third or fourth) do not appear to lead to increased ADR frequency.
Transmission model and health economic evaluation
The epidemiological modelling of pneumococcal diseases (IPD and PP) and health economic evaluation of various vaccination strategies were conducted by the Center for Health Economics Research (CHERH) at the University of Hannover. Here, the main assumptions and results of the modelling are described. The full project report (in German) is available from the RKI website: www.rki.de/impfen > Forschungsprojekte.
Model structure
As mentioned, herd protection through childhood vaccination with PCV13 strongly influences serotype distribution of pneumococcal diseases in all age groups, including the target group of people aged ≥60 years. Two circumstances are decisive: 1. Children are the main source of pneumococcal infection for older people, because children are much more frequently nasopharyngeal carriers of percentile of the GMC ratios; the horizontal line within the box is the median ratio. A ratio of >1 means that the GMC was higher at the same point in time after the 2nd dose than after the 1st dose pneumococci than are older adults [113] . 2. The pneumococcal conjugate vaccines used to vaccinate infants provide selective protection from nasopharyngeal colonisation with vaccine serotypes. Therefore, they influence the serotype mix in colonised children and, thus, the serotype mix in disease cases in all age groups as well.
To take this phenomenon into account, a dynamic transmission model was developed. Pneumococcal serotypes were divided into five groups: PCV7 serotypes, additional serotypes in PCV13 except serotype (ST) 3, ST 3, additional serotypes in PPSV23 (minus ST 6A), and non-vaccine serotypes. ST 3 is a special case because vaccination efficacy against this serotype is questionable (see Sect. 4). In the base case, it is assumed that PPSV23 and PCV13 are half as effective against ST 3 as against the other serotypes contained in the respective vaccine. The transmission parameters that determine nasopharyngeal colonisation were calibrated based on the effects observed in Germany since introduction of universal infant vaccination and -under the assumption of stable vaccine uptake in infants -used to predict future development of case numbers and serotype mix in disease cases (IPD, PP) among older adults. Data on the varying invasiveness of different serotypes were taken into account [114, 115] .
As the next step, the epidemiological and health economic effects of the following vaccination strategies were examined: 5 one-time vaccination with PPSV23 5 one-time vaccination with PCV13 5 sequential vaccination with PCV13 + PPSV23 5 repeated vaccinations with PPSV23 after initial vaccination with PPSV23 5 repeated vaccinations with PPSV23 after sequential initial vaccination with PCV13 + PPSV23
In the base case, modelling was based on the assumptions listed in . Table 10 , which were varied in several sensitivity analyses.
Assessment of epidemiological effects
The model predicts a continued marked reduction in the percentage of PCV13 serotypes in pneumococcal disease cases among older adults, resulting from herd protection through infant vaccination. Therefore, in the coming years, the share of pneumococcal disease episodes preventable by vaccination of older adults with PCV13 would be limited to <30 % of all cases, even with a theoretical vaccine efficacy of 100 % and vaccine uptake of 100 %.
The main epidemiological and health economic results of the model are summarised in . . Table 11 shows the results for the base case. . Table 12a shows the results of a sensitivity analysis on the assumption of 0 % efficacy of PPSV23 against PP (with PCV13 efficacy unchanged). . Table 12b and c show the results for these two scenarios on the additional assumption that PCV13 is as effective against ST 3 as against the other vaccine serotypes, while PPSV23 is half as effective against ST 3 (in . Table 12c , only against IPD).
Results of vaccination strategies with one-time vaccination
The results show that the vaccination of older adults with PPSV23 can, on the whole, prevent more cases, and the numbers needed to vaccinate (NNV) to prevent hospitalisation or death are lower than for vaccination with PCV13. Therefore, PPSV23 is the superior choice for a vaccination strategy with one vaccine only.
One-time vaccination with PPSV23 results in NNVs to prevent one hospitalisation with IPD or PP in the range of 648-801, depending on age at vaccination. NNVs to prevent one death range from 4,247 to 6,690. Few additional cases could be prevented by sequential vaccination with PCV13 + PPSV23. In the base case, depending on age at vaccination, about 3,500-6,100 older adults must be vaccinated with PCV13 in addition to PPSV23 to prevent one additional hospitalisation, and 18,000-38,000 to prevent one additional death. In contrast, doubling the PPSV23 vaccine uptake in older adults from the current c. 30 % to 60 % could roughly double the number of prevented cases.
Results of vaccination strategies with repeated vaccinations
Because of the limited duration of protection provided by PPSV23, and the lack of a booster effect, repeating the vaccination at regular intervals appears plausible. The duration of protection and the frequency and severity of side effects must be taken Because the risk of falling ill with a pneumococcal infection increases with age, both the individual and epidemiological benefits of vaccination increase with age. Thus, the sum of re-vaccinations can prevent far more cases than one-time vaccination, and the NNVs are markedly lower. That also applies to a sensitivity analysis on the assumption that repeat vaccinations are only 75 % as effective as the initial vaccination (data not shown). The effects resulting from an initial sequential vaccination with PCV13 and PPSV23, instead of PPSV23 alone, were also modelled. In the base case and in scenarios shown in . Table 12a . Table 12c , sequential vaccination leads to noteworthy numbers of additional prevented hospitalisations and deaths, with reasonable NNVs and costs of <€ 100,000 per QALY. This scenario assumes a lack of efficacy of PPSV23 against non-bacteraemic PP and lower efficacy against ST 3 for PPSV23, but not for PCV13. STIKO considers this scenario highly improbable for the reasons given in Sect. 4 and 6.2. The scenario was modelled to get an impression of how drastic the assumptions in favour of PCV13 need to be to achieve reasonable NNVs and costs per QALY for the sequential vaccination.
Health economic evaluation
Assuming a vaccine uptake of 30 % of each cohort reaching age 60 (or 65 or 70) in 2016-2020, and taking into account the direct and indirect costs (work lost), the various vaccination strategies result in the figures shown in . Table 11 and 12.
In the base case (. Table 12a ).
The costs of sequential vaccination with PCV13 + PPSV23 are very high: in the base case € 216,000-375,000 per additional prevented hospitalisation and € 306,000-366,000 per additional QALY gained. In the scenario that assumes no efficacy of PPSV23 against PP (. Table 12a), the costs of sequential vaccination per additional prevented hospitalisation and QALY gained are still around 2-4.5 times higher than those of vaccination with PPSV23 alone.
In the vaccination strategies with repeated PPSV23 vaccinations, the differences between the two strategies (initial vaccination with PPSV23 alone vs. initial sequential vaccination) are even greater. In the base case, vaccination with PPSV23 alone would incur costs of about € 6,700-6,900 per hospitalisation prevented, and € 12,000-13,000 per QALY gained. The costs of sequential vaccination, however, are extremely high: € 426,000 to € 2.8 million per additional hospitalisation prevented and QALY gained, respectively. 
Efficacy of PCV13
5 against VT-PP 45.9 %* CAPITA study [22] 5 against VT-IPD 76.6 %* CAPITA study [22] 5 duration of protection ** 8.2 years CAPITA study and English data on the duration of protection in children [78] 5 against serotype 3 Half efficacy see Sect. 4 However, the confidence intervals of the efficacy estimates against IPD are so wide that a clinically relevant efficacy difference between PCV13 and PPSV23 against vaccine serotype disease cannot be ruled out with certainty. With regard to reactogenicity, RCTs with a direct comparison of the two vaccines did not show any significant differences either, except for a slightly higher occurrence of muscle pain after PPSV23.
Incidence of IPD
Crucial to the choice of the most effective vaccination strategy is the fact that the proportion of PCV13 serotypes in disease cases in all age groups has dropped significantly through herd protection provided by PCV13 vaccination of infants. If in the 5-year period of 2016-2020, according to the current vaccine uptake, 30 % of people who reach 60 years are vaccinated with a single dose of PPSV23, an estimated cumulative total of 2,253 hospitalisations and 270 deaths from pneumococcal diseases can be prevented in their lifetimes, compared to no vaccination (NNV: 801 per hospitalisation, 6,690 per death). If the vaccine uptake were doubled, the number of hospitalisations and deaths prevented would also roughly double, while the NNV would remain the same. Additional vaccination with a single dose of PCV13 would prevent a cumulative total of only 296 further hospitalisations and 47 further deaths; i. e. around 5-7 times more vaccinations with PCV13 than with PPSV23 were needed to prevent one additional hospitalisation or one additional death.
A significant limitation of the efficacy of pneumococcal vaccination is the limited duration of protection. For that reason, STIKO also analysed the evidence on efficacy and reactogenicity of re-vaccinations with PPSV23. In the first 2 months after a second vaccination with PPSV23, antibody levels were lower than in the first 2 months after the initial vaccination. However, 1-10 years after re-vaccination antibody levels were as high or even higher than 1-10 years after the initial vaccination. That might mean that re-vaccination provides somewhat lower protection than the initial vaccination. To our knowledge, there are no studies with clinical endpoints examining this question.
Because the risk of contracting a pneumococcal infection increases with age, both the individual and epidemiological benefit of vaccination increase with age. That leads to lower NNVs and costs per case prevented for re-vaccinations, even if a 25 % lower efficacy than for the initial vaccination is assumed.
The costs of a vaccination strategy consisting of initial and re-vaccinations with NNV Number needed to vaccinate, QALY quality-adjusted life year Tätigkeitsberichte PPSV23 alone and a sequential strategy (initial vaccination with PCV13 + PPSV23, re-vaccinations with PPSV23) were compared. In both strategies, initial vaccination is assumed to occur at age 60 years. In the base case, the costs of the PPSV23-only strategy were € 6,700 per hospitalisation prevented, and € 12,800 per QALY gained. Thus, vaccination of older adults with PPSV23 (applied to costs per QALY) is clearly more cost-effective than, for example, rotavirus vaccination of infants (about € 120,000 per QALY [119] ). The strategy of sequential initial vaccination would incur extremely high additional costs of about € 1.5 million per hospitalisation prevented, and € 2.8 million per QALY gained. Based on these findings and considerations, STIKO continues to recommend vaccination with PPSV23 for all adults at age 60 years. Additionally, STIKO considers re-vaccinations with PPSV23 with an interval of ≥6 years useful from a medico-epidemiological perspective to maintain vaccine protection. The current prescribing information of PPSV23 limits re-vaccination to "persons at increased risk of severe pneumococcal disease. " The indication for re-vaccination of healthy older adults should therefore be evaluated individually. Sequential vaccination with PCV13 and PPSV23 is not recommended as a standard vaccination for older adults because of the low number of additional preventable cases, very high NNV, and high additional costs.
Acceptance of PPSV23, in particular of re-vaccinations, could be impaired by the known reactogenicity of the vaccine. Based on the available data, reactions to the vaccination (e. g. painful local swelling, headache, pain in the limbs) appear to occur more frequently after re-vaccinations than after the initial vaccination. Vaccinees must be informed of this. Stronger reactogenicity was observed especially at intervals of <5 years between vaccinations. At intervals of >5 years, time between vaccinations appears to not further influence the frequency and severity of adverse events. Furthermore, these reactions mostly appear to last only 2-3 days, as controlled studies have shown.
In STIKO's opinion the balance of benefits (protection from a severe disease with considerable case fatality) and risks of vaccination (painful side effects of limited duration) clearly favours repeated vaccinations. STIKO advocates accompanying implementation of this vaccination recommendation with a reactogenicity study to examine whether the frequency and severity of the reactions after re-vaccinations in practice are in the same range as expected based on published data.
To enhance the epidemiological effects of the PPSV23 vaccination recommendation, a significant increase in vaccine uptake among older adults from the current 30 % is desirable. To address this, the reasons for the low vaccine uptake especially in the states of the former West Germany should be established, and acceptance of the vaccination should be increased through customised measures. Vaccine uptake in the target group needs to be tracked regularly to evaluate such measures. Furthermore, there is urgent need to continue laboratory-based surveillance of serotype distribution in IPD cases, and expand it to include studies of serotype distribution in non-bacteraemic pneumococcal pneumonia. Understanding the serotype distribution is an indispensable prerequisite for effectively assessing various vaccination strategies, also with regard to the higher-valent pneumococcal conjugate vaccines expected in the future.
STIKO recommendations on riskbased vaccination of people with certain underlying diseases were not part of this evaluation. Updated STIKO recommendations for risk-based vaccination against pneumococci can be found in the revised table 2 of the STIKO recommendations. The scientific rationale for these recommendations has been published separately (in Epid Bull 37/2016, in German). Table A3 GRADE profile for safety aspects of PPSV23 Wide confidence interval. 4 Confounding by indication likely; no adjusted RRs are reported.
